SCYX (Scynexis) Earnings per share growth rate in current year

Official company branding of scynexis.com (SCYX)

The annual EPS growth rate reflects profitability dynamics, with the indicator currently at -115.30. The SCYNEXIS, Inc. (SCYX) strategy relies on an alliance with GSK for the global promotion of its technological base. Revenue is generated through the sale of Brexafemme and partnership royalties. Business stability is guaranteed by a large-scale licensing agreement, which mitigates operational risks and ensures a steady profit inflow.

scynexis.com (SCYX): Net earnings per share growth this year from 07/04/2022 to 11/10/2026

Analytical breakdowns and data insights for company scynexis.com (SCYX)

- current price and projected stock value:
Quote Chart SCYNEXIS|SCYX - Analyst Consensus Forecast
- business market valuation indicators:
Market Value SCYX|SCYX - Enterprise Value
- balance sheet equity data:
Accounting Value per Share SCYNEXIS|SCYX - Company Net Assets|Market Cap to Book Value Multiple scynexis.com|SCYX - Company Total Assets
- debt burden and liquidity indicators:
Total Debt to Capital Coefficient SCYNEXIS, Inc.|SCYX - Long-Term Debt to Equity|Current Liabilities to Capital SCYNEXIS|SCYX - Company Debts|Debt to Book Value Ratio SCYX|SCYX - Company Long-Term Debt|Short-Term Debt Volume SCYNEXIS|Interim Coverage Ratio scynexis.com
- net income and valuation ratios data:
SCYX - Net Profit|Future Profit SCYNEXIS, Inc.|SCYX - Price to Earnings Ratio|Projected Price to Earnings Ratio SCYNEXIS|SCYX - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation SCYX|SCYX - Operating profit EBITDA|Net earnings per one share for the last twelve months SCYNEXIS|SCYX - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last 12 months scynexis.com|SCYX - Earnings growth in current year|Consensus forecast of earnings per share growth for next year SCYNEXIS, Inc.
Basic company analysis:Scynexis
Mass-produced product of SCYNEXIS, Inc.

SCYNEXIS, Inc. (SCYX) minimizes the risks of single-product dependence through the strategic licensing of its antifungal developments to global partners. This indicator measures the annual change in net earnings per share, reflecting the efficiency of business scaling. Growth in this metric confirms an increase in specific profitability, whereas debt load triggers its decline. It is critical for investors to monitor the stability of this trend to assess capital resilience. Analyzing the shift in earnings per share compared to the previous year allows for the timely diagnosis of a fundamental downturn.

Main competitors

Earnings per share trend in current year SMMT (Summit Therapeutics plc)|MRNA (Moderna Corp) - Earnings growth in current year|Earnings per share growth rate in current year SutroVax PCVX|Earnings growth in current year TARS|Net earnings per share growth this year cormedix.com CRMD|Seres Therapeutics, Inc. - Net earnings per share growth this year|Net earnings per one share growth for the current year SPRO (Spero Therapeutics Inc)|AN2 Bio - Earnings growth in current year|Expected net earnings per share growth this year PolyPid Ltd. PYPD|LakeShore Biopharma Co. (LSB) - Earnings per share growth in current year|Earnings per share growth rate in current year Iterum Therapeutics (ITRM)|Earnings per share growth in current year BiomX Inc|Earnings per share growth this year SNGX (BioPharma Bio)|Earnings per share growth in current year 60 Degrees Pharmaceuticals (SXTP)|Expected net earnings per share growth this year oragenics.com|Earnings per share growth in current year OpGen, Inc. OPGN